Immunotherapy in elderly head and neck cancer patients: a systematic review and meta-analysis

Front Oncol. 2024 May 10:14:1395838. doi: 10.3389/fonc.2024.1395838. eCollection 2024.

Abstract

Introduction: Over the past years, there has been a growing interest in the role of immunotherapy in locally advanced (LA) and recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). High-quality data from prospective trials are lacking for the elderly subpopulation. This systematic review and meta-analysis aims to review the efficacy and safety of immunotherapy in older patients.

Methods: A systematic literature search was conducted. Randomized clinical trials providing outcome data on a subgroup of elderly (>65 years old) were available for meta-analysis. Primary outcomes of interest were OS and PFS for efficacy analysis.

Results: Seven studies were included in the systematic review and four in the efficacy analysis. The pooled analysis of OS and PFS showed a consistent benefit (HR 0.78 and 0.91, respectively).

Conclusions: Immunotherapy may be an effective and well-tolerated treatment option in the elderly population, but more prospective and randomized data are needed.

Systematic review registration: PROSPERO (CRD42022333891).

Keywords: elderly; head and neck cancer; immunotherapy; locally advance head and neck cancer; recurrent and metastatic head and neck cancer.

Publication types

  • Systematic Review

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.